Qualitek Labs Ltd. (QLL) — Tipsheet

Qualitek Labs takes on ₹91 cr in new bank debt

Tipsheet Editorial — Wed, 03 Jun 2026 16:47:17 GMT

The nano-cap testing firm quadruples its borrowings after 77% revenue growth, pledging industrial buildings and family property as security.

What’s new

Qualitek Labs secured a ₹91.31 cr facility from HDFC Bank, covering term loans, guarantees, cash credit, and capex letters of credit.
The facility is ~19% of the company's ₹475 cr market cap and dwarfs the prior ₹12.8 cr in outstanding debt.
The company pledged two Haryana industrial buildings, property from SKM Realcon, and corporate guarantees as security.

Why it matters

This is a bet on growth financed with a balance sheet that was nearly debt-free. The ₹91.31 cr facility is 19% of market cap and seven times the prior borrowings. For a company with ₹124.5 cr in revenue, the new debt load is material.

What we’re watching

How the term loans and capex letters of credit are deployed.
Whether revenue growth can service the new interest costs.
The impact on balance sheet ratios like debt-to-equity.

The full read

Qualitek Labs landed a ₹91.31 crore credit facility from HDFC Bank. That is 19% of its ₹475 crore market cap. The company's prior outstanding debt stood at ₹12.8 crore. The new facility covers term loans, bank guarantees, cash credit, and capex letters of credit. To secure it, Qualitek pledged two Haryana industrial buildings, property held by SKM Realcon Private Limited, and corporate guarantees from related parties. The sanction came May 26; the board approved it June 3. The context matters: Qualitek grew revenue 77% in FY26 to ₹124.5 crore. This is a major expansion of financial capacity for a nano-cap company. It increases the debt load by more than seven times. Hardly incremental. The open question is whether the growth can support it.

Primary source: BSE · NSE

Qualitek Labs guides for 35-40% revenue growth in FY27

Tipsheet Editorial — Wed, 20 May 2026 20:53:20 GMT

The nano-cap lab-services company sets explicit FY27 targets in its MD&A, signaling confidence in its acquisition-led strategy after a year of strong execution.

What’s new

FY27 guidance: revenue growth 35-40%, EBITDA margin 25-27%, PAT margin 15-17%.
Guidance supplements already-disclosed H2 FY26 and FY26 results.
Nano-cap (₹434 cr) sets explicit targets, material for investor expectations.

Why it matters

For a nano-cap, explicit guidance of this granularity is rare and signals management confidence in its acquisition-led growth strategy. It moves Qualitek from a reported-history stock to a modelled-outlook stock, giving analysts and investors a concrete benchmark through FY27.

What we’re watching

Whether quarterly results align with the ambitious FY27 targets.
Impact of acquisitions on margin expansion to guided 25-27% EBITDA.
Any market reaction or analyst upgrades following the guidance.

The full read

Qualitek Labs has done something many nano-caps avoid: it gave explicit FY27 guidance. Revenue growth of 35-40%, EBITDA margins of 25-27%, and PAT margins of 15-17% are now on the table. The numbers supplement the already-disclosed FY26 results, which were known from prior filings, but the forward-looking targets are new. For a company with a market cap of ₹434 crore, this level of disclosure shifts the narrative from rearview reporting to forward accountability. The guidance suggests management expects the acquisition momentum and operational discipline to continue. The test will be whether quarterly results deliver against these targets. If they do, Qualitek could re-rate; if not, the stock may lose credibility. For now, the direction is clear.

Primary source: BSE · NSE

Qualitek Labs FY26 sales jump 77%, profit up 90%

Tipsheet Editorial — Wed, 20 May 2026 20:42:59 GMT

Consolidated revenue hits ₹124.5 crore as acquisitions kick in; net profit at ₹14.6 crore.

What’s new

Revenue surged 77% to ₹124.5 crore in FY26.
Net profit jumped 90% to ₹14.6 crore.
Growth driven by acquisitions and operational expansion.

Why it matters

Qualitek Labs has posted exceptional growth, nearly doubling profit on a 77% revenue jump. The unmodified audit opinion adds confidence. But with the core results already anticipated, the focus shifts to whether the company can maintain this momentum organically.

What we’re watching

FY27 revenue guidance and organic growth split.
Margins: whether acquisition integration costs pressure profitability.
Any update on new acquisition pipeline.

The full read

Qualitek Labs closed FY26 with numbers that would grab any headline: revenue up 77% to ₹124.5 crore, profit up 90% to ₹14.6 crore, and a clean audit opinion. The board approved these results in a routine meeting — routine because the market had already been guided toward strong growth. Acquisitions did the heavy lifting, but the question now is what FY27 looks like when the organic base is larger and deal-driven momentum is harder to repeat. For a company that has just proven it can execute on M&A, the next chapter is about sustaining that execution without needing a new acquisition every quarter.

Primary source: BSE · NSE

Qualitek Labs revenue surges 77% to ₹124.5 cr in FY26

Tipsheet Editorial — Wed, 20 May 2026 20:33:46 GMT

Net profit jumps 90% to ₹14.6 cr, driven by acquisitions and new NABL accreditation

What’s new

Revenue up 77% to ₹124.5 cr; profit up 90% to ₹14.6 cr
Acquisitions of Interstellar Testing Centre and LabOps Global drive growth
Second lab gets NABL accreditation

Why it matters

For a nano-cap, 90% profit growth on 77% revenue growth is exceptional. The acquisitions are already adding to the bottom line. The challenge now is integrating two new labs and proving the growth can continue without further M&A.

What we’re watching

Whether NABL accreditation leads to new contract wins
Integration of Interstellar and LabOps Global
Margin trajectory in FY27

The full read

Qualitek Labs more than doubled its topline in FY26, riding two acquisitions and a second NABL accreditation. The 77% revenue jump to ₹124.5 crore and 90% profit growth to ₹14.6 crore are outsized for a nano-cap, but the question is whether this is a one-time boost or the start of a compound story. The company bought Interstellar Testing Centre and LabOps Global, both food testing labs, and secured NABL backing for its second facility. That gives it capacity. The next year will show how much of the growth was M&A math and how much was organic.

Primary source: BSE · NSE